Robert W. Carlson, MD | Authors


mTOR Inhibitors in the Treatment of Breast Cancer

January 15, 2013

Efforts to identify clinical biomarkers of response or resistance to mTOR inhibitors are ongoing. This review will summarize results of preclinical and clinical studies as well as ongoing clinical trials with mTOR or dual PI3K/mTOR inhibitors.

Meta-analysis: Methods, Strengths, and Weaknesses

March 01, 2000

Meta-analysis is a systematic, quantitative approach to the combination of data from several clinical trials that address the same question. This analytic approach can help resolve questions that remain unclear from the results

Quality of Life Issues in the Treatment of Metastatic Breast Cancer

March 01, 1998

The treatment of metastatic breast cancer involves the sequential selection and delivery of hormonal therapies and cytotoxic chemotherapies. The available therapies for metastatic breast cancer are rarely curative, although high rates of response and modest prolongation of survival may be achieved in association with varying degrees of treatment-related toxicity.